Reference pricing and health technology assessment are policies commonly applied in order to obtain more value for money from pharmaceuticals. This study focussed on decisions about the initial price and reimbursement status of innovative drugs and discussed the consequences for market access and cost. Four countries were studied: Germany, The Netherlands, Sweden and the United Kingdom. These countries have operated one, or both, of the two policies at certain points in time, sometimes in parallel. Drugs in four groups were considered: cholesterol-lowering agents, insulin analogues, biologic drugs for rheumatoid arthritis and "atypical" drugs for schizophrenia. Compared with HTA, reference pricing is a relatively blunt instrument for obtaining value for money from pharmaceuticals. Thus, its role in making reimbursement decisions should be limited to drugs which are therapeutically equivalent. HTA is a superior strategy for obtaining value for money because it addresses not only price but also the appropriate indications for the use of the drug and the relation between additional value and additional costs. However, given the relatively higher costs of conducting HTAs, the most efficient approach might be a combination of both policies.

Additional Metadata
Keywords Cost-effectiveness analysis, Health policy, Pharmaceuticals, Reimbursement
Persistent URL dx.doi.org/10.1007/s10198-010-0274-y, hdl.handle.net/1765/25133
Citation
Drummond, M., Jönsson, B., Rutten, F.F.H., & Stargardt, T.. (2011). Reimbursement of pharmaceuticals: Reference pricing versus health technology assessment. The European Journal of Health Economics, 12(3), 263–271. doi:10.1007/s10198-010-0274-y